Le placebo, quel rôle dans la recherche clinique ? (notice n° 795841)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04569cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250123120700.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Petron-Bardou, Camille |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Le placebo, quel rôle dans la recherche clinique ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2013.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 72 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Résumé La réponse à l’administration d’une substance par définition pharmacologiquement inactive constitue l’effet placebo. L’intrication des différents mécanismes impliqués rend impossible leur analyse indépendante et complique l’étude de l’effet placebo. Celui-ci s’inscrit dans un contexte thérapeutique global, lié à l’activation de circuits neurofonctionnels généraux et spécifiques. Il repose sur la mise en jeu des mécanismes d’attente et de conditionnement sous l’influence de la dopamine et du système opioïde, confirmée par la neuro-imagerie. Différentes structures cérébrales vont permettre la sélection d’informations pertinentes pour l’obtention d’une récompense et entraîner la mémorisation de la réponse obtenue afin de favoriser ce circuit lors de la prochaine administration du médicament. Le médicament placebo a donc une action neurobiochimique indirecte justifiant son effet. Ainsi, le recours au placebo en recherche clinique paraît incontournable, car il assure aux études leur validité scientifique en montrant l’action propre de la molécule. Son utilisation reste controversée par des questionnements éthiques. Consacré par l’Evidence Based Medicine, le placebo devient indispensable en recherche après la Seconde Guerre mondiale. Ensuite, la déclaration d’Helsinki de 1964 viendra encadrer puis restreindre l’usage du placebo, afin de garantir les droits des patients. C’est la recherche active d’un compromis entre éthique et utilisation du placebo, à chaque étape des études, à travers le recours au double aveugle, le consentement éclairé, l’encadrement du Comité de Protection des Personnes, qui assurera la validité des études. Éthiquement recevables, car scientifiquement valides, elles seront alors bénéfiques aux patients. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Abstract The response following the administration of a substance by definition pharmacologically inactive constitutes the placebo effect. Intrication of various mechanisms makes it impossible to analyze them separately and complicates the study of the placebo effect. This is a global therapeutic context, related to the activation of general and specific neurofunctional circuitry. The placebo effect is based on expectation and conditioning mechanisms under the influence of dopamine and opioid system as documented by neuroimaging studies. Cerebral structures such as the amygdala, the hippocampus and the nucleus accumbens allow for the selection of relevant and rewardful information. Memorizing the response will lead to the reactivation of the same circuitry at the next medication time. The placebo drug thus has an indirect neurobiochemical action, which explains its effect. Using a placebo in clinical research may seem unavoidable atfirst sight, as it ensures scientific validity to studies. But in medical research, this use is controversial, because of the obvious ethical questions it raises. Recognized by Evidence Based Medicine, placebo becomes essential to research after the Second World War. Later, the Helsinki declaration of 1964 will organize then restrict this placebo use, in order to safeguard the patients ‘ rights. It is the pursuit of a compromise between the code of ethics and the use of placebo, by using double placebo, informed consent and the person’s consent committee’s supervision, that will ensure scientific validity to studies. Then, ethically acceptable as scientifically valid, these trials will be useful for the patients. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychiatrie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | essai clinique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | placebo |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | éthique médicale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | clinical trial |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychiatry |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | placebo |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | clinical ethics |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Venel, Véronique |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bardot, Virginie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Airagnes, Guillaume |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lecovec, Gaëlle |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Carof-Ben Hamida, Myriam |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Diquet, Bertrand |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lascar, Philippe |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Perspectives Psy | 52 | 4 | 2013-11-01 | p. 326-331 | 0031-6032 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-perspectives-psy-2013-4-page-326?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-perspectives-psy-2013-4-page-326?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux